Get notified when LGVN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The company's auditor has expressed substantial doubt about its ability to continue as a going concern, with cash only funding operations into Q1 2026.
- Dual-class (new) — The dual-class structure concentrates voting power in Class B shares, with three holders controlling approximately 29% of combined voting power.
- Concentration (new) — The company's entire pipeline is based on a single product candidate, laromestrocel, across three indications.
Longeveron launches at-the-market offering to sell up to $10.7M of stock at $0.76/share
Filed September 19, 2025 · ~1 min read
Key Changes
-
high
Longeveron may sell up to $10.7M of Class A common stock in an at-the-market offering via H.C. Wainwright, with net proceeds of $4.3M after fees.
The Offering verify on EDGAR → -
high
Proceeds are earmarked for clinical development of laromestrocel for HLHS, Alzheimer's, and pediatric DCM, plus working capital.
Use of Proceeds verify on EDGAR → -
high
New investors face immediate dilution of $0.08 per share, as pro forma net tangible book value is $0.68 vs. the $0.76 offer price.
Dilution verify on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade LGVN commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify